RT Journal Article
SR Electronic
T1 Intratumoral administration of CD1c (BDCA-1)<sup>+</sup> and CD141 (BDCA-3)<sup>+</sup> myeloid dendritic cells in combination with talimogene laherparepvec in immune checkpoint blockade refractory advanced melanoma patients: a phase I clinical trial
JF Journal for ImmunoTherapy of Cancer
JO J Immunother Cancer
FD BMJ Publishing Group Ltd
SP e005141
DO 10.1136/jitc-2022-005141
VO 10
IS 9
A1 Schwarze, Julia Katharina
A1 Tijtgat, Jens
A1 Awada, Gil
A1 Cras, Louise
A1 Vasaturo, Angela
A1 Bagnall, Christopher
A1 Forsyth, Ramses
A1 Dufait, Inès
A1 Tuyaerts, Sandra
A1 Van Riet, Ivan
A1 Neyns, Bart
YR 2022
UL http://jitc.bmj.com/content/10/9/e005141.abstract
AB Markup server — Error Not Found The page you were trying to reach could not be found. Please check the address for the page you were trying to reach. If you believe you have reached this page in error, you may contact us with any questions.